InvestorsHub Logo
Followers 9
Posts 450
Boards Moderated 0
Alias Born 09/29/2011

Re: None

Thursday, 09/12/2019 1:28:38 PM

Thursday, September 12, 2019 1:28:38 PM

Post# of 689138
GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

December 10 -11 Boston, MA, USA
Time: 11:40 am
Day: day Two

DCVax Technology: Leveraging Activated Dentritic Cells in Clinical 40 for GBM

Details:
- Exploring the history, biology and development of the platform technology DCVax
- Outlining the key aspects of the DCVax technology that contribute to the positive clinical results
- Designed to mobilize the entire immune system
- Designed to target not just one but the full set of biomarkers on the patient’s tumor
- DCVax is personalized, and targets the particular biomarkers expressed on that patient’s tumor
- Pinpointing highs and lows of clinical development to date

Speakers: Marnix Bosch

https://glioblastoma-drugdevelopment.com/seminar/dcvax-technology-leveraging-activated-dentritic-cells-in-clinical-40-for-gbm/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News